Statement to the current therapeutic options in neovascular age-related macular degeneration;Stellungnahme zu aktuellen therapeutischen möglichkeiten bei der neovaskulären altersabhängigen makuladegeneration: Aktualisiertes Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte

Ophthalmologe

Volumn 103, Issue 5, 2006, Pages 447-452

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; HUMAN; LASER COAGULATION; MEDICAL DECISION MAKING; OFF LABEL DRUG USE; OPHTHALMOLOGY; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION;

EID: 33646585768     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-006-1347-2     Document Type: Article

References (30)

1. http://www.cebm.net/downloads/Oxford_CEBM_Levels_5.rtf
2. http://www.emea.eu.int/pdfs/human/ withdrawal/7694506en.pdf
3. www.novartispharma.ch/news/pipeline/ ranibizumab-100106_d.pdf
4. Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113: 14-22
5. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372 e365
6. Axer-Siegel R, Ehrlich R, Rosenblatt I et al. (2004) Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 122: 453-459
7. Bressler SB, Pieramici DJ, Koester JM et al. (2004) Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management-TAP report No. 6. Arch Ophthalmol 122: 325-329
8. Chen Y, Wiesmann C, Fuh G et al. (1999) Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293: 865-881
9. Danis RP, Ciulla TA, Pratt LM et al. (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20: 244-250
10. Fung AE, Rosenfeld PJ, Reichel EZ: Intravitreal Avastin safety survey: results from the World Wide Web. In,Fung AE, Rosenfeld PJ, Reichel EZ (Hrsg). Intravitreal Avastin safety survey: results from the World Wide Web. Ft Lauderdale (2006) S.
11. Gillies MC, Simpson JM, Luo Wet al. (2003) A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121: 667-673
12. Gonzales CR (2005) Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25: 815-827
13. Gragoudas ES, Adamis AP, Cunningham ET, Jr. et al. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816
14. Jaissle GB, Szurman P, Bartz-Schmidt KU (2005) Empfehlung fur die Durchführung von intravitrealen Injektionen - Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft (DOG) und des Berufsverbands der Augenärzte Deutschland (BVA). Klin Monatsbl Augenheilkd 222: 390-395
15. Jonas JB, Kreissig I, Hugger P et al. (2003) Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 87: 462-468
16. Jonas JB, Kreissig I, Spandau UH et al. (2006) Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 141: 579-580
17. Jonas JB, Spandau UH, Kamppeter BA et al. (2006) Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye: in press
18. Manzano RP, Peyman GA, Khan P et al. (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26: 257-261
19. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26: 270-274
20. Mordenti J, Thomsen K, Licko V et al. (1999) Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution ora PL-GA microsphere formulation. Toxicol Sci 52: 101-106
21. Mulcahy MF, Benson AB, 3rd (2005) Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5: 997-1005
22. Pauleikhoff D, Bornfeld N, Gabel VP et al. (2005) Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte - Stellungnahme zur aktuellen Therapie der neovaskulären AMD. Klin Monatsbl Augenheilkd 222: 381-388
23. Reichel E (2005) Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? Ophthalmic Surg Lasers Imaging 36: 270-271
24. Shahar J, Avery RL, Heilweil G et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262-269
25. Slakter JS, Bochow TW, D'Amico DJ et al. (2006) Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113: 3-13
26. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110: 1517-1525
27. Spaide RF, Sorenson J, Maranan L (2005) Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina 25: 685-690
28. Spaide RF (2006) Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141: 149-156
29. Voelker M, Gelisken F, Ziemssen F et al. (2005) Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 243: 1241-1246
30. Westfall AC, Osborn A, Kuhl D et al. (2005) Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 123: 1075-1077